{"gene":"CHSY1","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2010,"finding":"CHSY1 is a secreted FRINGE enzyme required for chondroitin sulfate biosynthesis and for modulation of NOTCH signaling; loss of CHSY1 triggers massive production of JAG1 and subsequent NOTCH activation, which is reversed by wild-type but not catalytically dead CHSY1, demonstrating that its Fringe enzymatic activity is required for NOTCH regulation.","method":"Patient fibroblast secretion assay, RNAi knockdown in osteoblasts and glioblastoma cells, rescue with wild-type vs. catalytic-dead CHSY1 construct, zebrafish chsy1 morpholino knockdown","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (patient cells, RNAi, catalytic-dead rescue, in vivo zebrafish model) across human and fish systems","pmids":["21129727"],"is_preprint":false},{"year":2012,"finding":"Chsy1 is required for joint patterning and bone density in mice; Chsy1 knockout causes chondrodysplasia, decreased bone density, and ectopic joint formation in distal digits associated with a shift in cell orientation and imbalance in chondroitin sulfation.","method":"Chsy1 knockout mouse model; skeletal phenotype analysis, chondroitin sulfation assessment","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined skeletal and molecular phenotype, replicated human disease context","pmids":["22280990"],"is_preprint":false},{"year":2013,"finding":"CHSY1 has two glycosyltransferase activities (GlcUA transferase and GalNAc transferase) responsible for adding disaccharide units to chondroitin sulfate chains; the F362S missense mutation reduces both activities by ~50% and abrogates the cooperative elongation of chains initiated by chondroitin N-acetylgalactosaminyltransferase-1 (CSGALNACT1), demonstrating that CHSY1 regulates chain number/length cooperatively with CSGALNACT1.","method":"Recombinant wild-type and F362S mutant enzyme expression, in vitro glycosyltransferase activity assay, cell-based complementation","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis, single lab but multiple assays (both transferase activities + cooperative elongation tested)","pmids":["23811343"],"is_preprint":false},{"year":2015,"finding":"TGF-β induces CHSY1 expression in nucleus pulposus cells via MAPK signaling and activation of transcription factors c-Jun and Sp1; knockdown of c-Jun or Sp1 reduces TGF-β-mediated CHSY1 promoter activity and sulfated GAG accumulation; silencing CHSY1 reduces TGF-β-induced sulfated GAG accumulation.","method":"Real-time PCR, Western blot, lentiviral knockdown, CHSY1 promoter reporter assay in nucleus pulposus cells","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter + lentiviral KD with multiple pathway intermediates, single lab","pmids":["26356269"],"is_preprint":false},{"year":2017,"finding":"CHSY1 promotes hepatocellular carcinoma cell migration, invasion, and EMT by increasing cell-surface chondroitin sulfate that facilitates sonic hedgehog binding and Hedgehog pathway signaling; pharmacological Hedgehog inhibition reverses CHSY1-induced migration, invasion, and lung metastasis.","method":"CHSY1 overexpression and silencing in HCC cell lines, Hedgehog pathway inhibitor (vismodegib), in vivo lung metastasis assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with pharmacological rescue and in vivo model, single lab","pmids":["28652022"],"is_preprint":false},{"year":2018,"finding":"TGF-β1-mediated upregulation of CHSY1 mRNA in vascular smooth muscle cells occurs via a ROS/NADPH oxidase (Nox)-dependent pathway involving Smad2 linker region phosphorylation and MAPK activation; Nox inhibitors (DPI, apocynin) block both Smad2 linker phosphorylation and CHSY1 mRNA induction.","method":"Western blotting for signaling intermediates, qRT-PCR for gene expression, pharmacological inhibition of Nox, fluorescence-based ROS measurement in VSMCs","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors with orthogonal readouts, single lab","pmids":["30417274"],"is_preprint":false},{"year":2018,"finding":"Polyamines stimulate CHSY1 protein synthesis by destabilizing an RNA G-quadruplex (G4) structure in the 5'-UTR of CHSY1 mRNA (positions -202 to -117 relative to initiation codon); site-directed mutagenesis that prevents G4 formation abolishes the polyamine-stimulated increase in CHSY1 synthesis.","method":"Polyamine depletion/supplementation, CHSY1 protein quantification, NMR/structural analysis of 5'-UTR G4, site-directed mutagenesis of G4 sequences","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural (NMR) + mutagenesis + biochemical assay in single rigorous study demonstrating mechanism","pmids":["30401686"],"is_preprint":false},{"year":2019,"finding":"Endothelin-1 increases CHSY-1 protein levels in bovine aortic endothelial cells via ETB receptor signaling through Rho kinase and actin cytoskeletal rearrangement, leading to TGF-β type I receptor transactivation and Smad2C phosphorylation; this pathway does not involve MMPs.","method":"Western blotting with pharmacological inhibitors (BQ788, Y27632, cytochalasin D, GM6001) in BAECs","journal":"The Journal of pharmacy and pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors identifying pathway order, single lab","pmids":["30809816"],"is_preprint":false},{"year":2021,"finding":"ET-1 increases CHSY1 expression in human VSMCs through transactivation of both EGF receptor and TGF-β receptor; EGF receptor transactivation by ET-1 is dependent on NADPH oxidase (NOX) and ERK1/2 phosphorylation.","method":"Western blot with pharmacological inhibitors (bosentan, AG1478, DPI, SB431542) in human VSMCs","journal":"Cell journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors with orthogonal readouts, single lab","pmids":["34837677"],"is_preprint":false},{"year":2022,"finding":"CGRP from sensory nerves maintains intervertebral disc chondroitin sulfate homeostasis by regulating nucleus pulposus cell CHSY1 expression via the CGRP receptor component RAMP1 and CREB signaling; CHSY1 knockout mice phenocopy sensory denervation-induced ECM disorder, placing CHSY1 downstream of the CGRP/RAMP1/CREB axis.","method":"Genetic sensory denervation, CGRP knockdown mouse model, CHSY1 knockout mice, in vitro CGRP treatment with RAMP1/CREB pathway analysis","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (CHSY1 KO rescues denervation phenotype), multiple in vivo models, in vitro pathway validation","pmids":["36047655"],"is_preprint":false},{"year":2022,"finding":"Chsy1 deficiency in chondrocytes reduces extracellular matrix production and promotes endochondral osteogenesis by upregulating BMP signaling; BMP inhibitor LDN193189 rescues the ECM and osteogenesis defects caused by Chsy1 knockdown, placing Chsy1 as a negative regulator of BMP signaling in cartilage.","method":"Lentiviral Chsy1 knockdown in ATDC5 chondrocytes, BMP inhibitor rescue, gene expression analysis (Col2a1, Sox9, Col10a1, Runx2, Mmp13, Mmp3), primary OA rat chondrocyte experiments","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KD with pharmacological rescue and overexpression confirmation, single lab","pmids":["35390446"],"is_preprint":false},{"year":2023,"finding":"Chsy1 knockdown at peripheral nerve lesion sites decreases versican core protein accumulation in perineurium, associated with functional recovery of compound muscle action potential after end-to-side neurorrhaphy, indicating that CHSY1-synthesized chondroitin sulfate chains stabilize versican in the extracellular matrix.","method":"In vivo siRNA transfection in rat neurorrhaphy model, confocal microscopy, Western blotting, electrophysiology (compound muscle action potential)","journal":"Molecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD with molecular and functional readouts, single lab","pmids":["37175152"],"is_preprint":false},{"year":2023,"finding":"CHSY1 promotes CD8+ T cell exhaustion and PD-L1 upregulation through activation of the succinate metabolism pathway and the PI3K/AKT/HIF1A pathway, facilitating colorectal cancer liver metastasis; artemisinin inhibits CHSY1 activity and synergizes with anti-PD1.","method":"CRISPR/Cas9 in vivo mouse screen, in vitro and in vivo CHSY1 KD experiments, metabolomic analysis","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen + in vivo/in vitro validation + metabolomics, single lab","pmids":["37749638"],"is_preprint":false},{"year":2025,"finding":"CHSY1 forms four heterodimeric complexes (CHSY1-CHPF, CHSY1-CHPF2, CHSY3-CHPF, CHSY3-CHPF2) that polymerize chondroitin sulfate chains; cryo-EM structure and mutational analysis confirm that CHSY1 (and CHSY3) are the catalytically active bifunctional glycosyltransferases, while CHPF and CHPF2 play a stabilizing role; chain polymerization follows a non-processive, disruptive mechanism.","method":"Cryo-EM structure of CHSY3-CHPF complex, in vitro glycosylation assay with fluorescent substrates, mutational analysis of catalytic sites, in cellulo complementation assay","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure + in vitro reconstitution + mutagenesis + cell-based complementation in single preprint study","pmids":["bio_10.1101_2025.03.21.644485"],"is_preprint":true},{"year":2026,"finding":"CANT1 binds and stabilizes β-catenin, which translocates to the nucleus to activate CHSY1 transcription via TCF4; loss of CANT1/β-catenin signaling reduces CHSY1 expression and consequently reduces GAG and proteoglycan (ACAN) and COL2α1 production, causing skeletal ECM defects.","method":"Protein binding assays (CANT1-β-catenin interaction), nuclear translocation assay, CHSY1 gene activation assays, ECM component quantification in skeletal cells","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assay plus downstream gene activation and ECM readouts, single lab, abstract-level detail","pmids":["41928906"],"is_preprint":false}],"current_model":"CHSY1 is a bifunctional glycosyltransferase (GlcUA and GalNAc transferase) that, as part of heterodimeric complexes with CHPF or CHPF2, polymerizes chondroitin sulfate chains on proteoglycans via a non-processive mechanism; it is secreted and acts as a FRINGE enzyme to attenuate NOTCH signaling, modulates BMP signaling in cartilage, facilitates sonic hedgehog binding at the cell surface, regulates versican stability in the ECM, and is transcriptionally controlled by TGF-β/MAPK, CGRP/RAMP1/CREB, and CANT1/β-catenin/TCF4 pathways, with its own translation regulated post-transcriptionally by polyamine-mediated unfolding of a 5'-UTR RNA G-quadruplex."},"narrative":{"mechanistic_narrative":"CHSY1 is a secreted bifunctional glycosyltransferase that polymerizes chondroitin sulfate chains on proteoglycans, thereby governing extracellular matrix composition and several developmental signaling pathways [PMID:21129727, PMID:23811343]. It carries two distinct catalytic activities—glucuronic acid (GlcUA) transferase and N-acetylgalactosamine (GalNAc) transferase—that add disaccharide units during chain elongation, acting cooperatively with CSGALNACT1 to control chain number and length [PMID:23811343]. CHSY1 functions within heterodimeric complexes with the stabilizing subunits CHPF or CHPF2 and elongates chains by a non-processive, disruptive mechanism [PMID:bio_10.1101_2025.03.21.644485]. Through its enzymatic output, CHSY1 acts as a FRINGE enzyme that restrains NOTCH signaling: its loss drives excess JAG1 production and NOTCH activation, a phenotype rescued by catalytically active but not catalytic-dead enzyme [PMID:21129727]. The chondroitin sulfate it produces additionally negatively regulates BMP signaling in chondrocytes [PMID:35390446], facilitates cell-surface sonic hedgehog binding [PMID:28652022], and stabilizes the matrix proteoglycan versican [PMID:37175152]. In vivo, CHSY1 is required for skeletal development, controlling joint patterning, bone density, and chondroitin sulfation balance [PMID:22280990], and its activity sustains intervertebral disc matrix homeostasis downstream of sensory CGRP/RAMP1/CREB signaling [PMID:36047655]. CHSY1 expression is induced transcriptionally by TGF-β via MAPK/c-Jun/Sp1 [PMID:26356269] and by CANT1/β-catenin/TCF4 signaling [PMID:41928906], while its translation is controlled post-transcriptionally by polyamine-mediated unfolding of a 5'-UTR RNA G-quadruplex [PMID:30401686]. CHSY1 also promotes tumor progression in hepatocellular and colorectal carcinoma through Hedgehog and PI3K/AKT/HIF1A-coupled metabolic mechanisms [PMID:28652022, PMID:37749638].","teleology":[{"year":2010,"claim":"Established that CHSY1's chondroitin sulfate-synthesizing enzymatic activity is functionally required to restrain NOTCH signaling, defining it as a FRINGE enzyme rather than a passive matrix builder.","evidence":"Patient fibroblast secretion assay, RNAi in osteoblasts/glioblastoma, catalytic-dead rescue, and zebrafish morpholino knockdown","pmids":["21129727"],"confidence":"High","gaps":["Molecular link between chondroitin sulfate output and JAG1/NOTCH suppression not mechanistically resolved","Does not define the enzymatic reaction chemistry"]},{"year":2012,"claim":"Demonstrated that Chsy1 is essential in vivo for skeletal patterning, connecting its biochemical role to joint formation, bone density, and chondroitin sulfation balance.","evidence":"Chsy1 knockout mouse with skeletal and chondroitin sulfation phenotyping","pmids":["22280990"],"confidence":"High","gaps":["Signaling pathway driving the ectopic joint phenotype not identified at this stage","Cell-autonomous versus matrix-mediated effects not separated"]},{"year":2013,"claim":"Defined CHSY1's dual catalytic activities and showed it cooperates with CSGALNACT1, explaining how it regulates chondroitin chain number and length.","evidence":"Recombinant wild-type/F362S enzyme in vitro glycosyltransferase assays and cell-based complementation","pmids":["23811343"],"confidence":"High","gaps":["Structural basis of bifunctional catalysis not resolved","Composition of the active enzyme complex not yet defined"]},{"year":2015,"claim":"Identified the first transcriptional input to CHSY1, showing TGF-β induces it through MAPK/c-Jun/Sp1 to drive sulfated GAG accumulation.","evidence":"Promoter reporter, lentiviral knockdown, and expression analysis in nucleus pulposus cells","pmids":["26356269"],"confidence":"Medium","gaps":["Direct c-Jun/Sp1 binding to the CHSY1 promoter not mapped","Single cell type tested"]},{"year":2018,"claim":"Revealed post-transcriptional control of CHSY1, showing polyamines stimulate its translation by destabilizing a 5'-UTR RNA G-quadruplex.","evidence":"Polyamine depletion/supplementation, NMR structural analysis, and G4-disrupting mutagenesis","pmids":["30401686"],"confidence":"High","gaps":["Physiological trigger linking polyamine levels to chondroitin sulfate demand not established","Trans-acting factors recognizing the G4 not identified"]},{"year":2018,"claim":"Extended TGF-β control of CHSY1 to vascular smooth muscle via a ROS/Nox-dependent Smad2 linker phosphorylation route.","evidence":"Pharmacological Nox inhibition with signaling and qRT-PCR readouts in VSMCs","pmids":["30417274"],"confidence":"Medium","gaps":["Inhibitor-based pathway inference without genetic confirmation","Direct effect on chondroitin sulfate output not measured"]},{"year":2019,"claim":"Mapped an endothelin-1/ETB receptor pathway that raises CHSY1 protein through Rho kinase and TGF-β receptor transactivation in endothelial cells.","evidence":"Western blot with sequential pharmacological inhibitors in bovine aortic endothelial cells","pmids":["30809816"],"confidence":"Medium","gaps":["Relies entirely on pharmacological inhibitors","Transcriptional versus translational control not distinguished"]},{"year":2021,"claim":"Showed ET-1 regulation of CHSY1 in human VSMCs converges on dual EGFR and TGF-β receptor transactivation, with EGFR arm NOX/ERK-dependent.","evidence":"Western blot with multiple inhibitors in human VSMCs","pmids":["34837677"],"confidence":"Medium","gaps":["No genetic loss-of-function validation","Downstream chondroitin sulfate consequences not assessed"]},{"year":2022,"claim":"Placed CHSY1 downstream of sensory CGRP/RAMP1/CREB signaling as the effector maintaining intervertebral disc chondroitin sulfate homeostasis.","evidence":"Genetic sensory denervation, CGRP knockdown, and CHSY1 knockout mice with in vitro pathway validation","pmids":["36047655"],"confidence":"High","gaps":["Direct CREB occupancy of the CHSY1 locus not shown","Mechanism of chondroitin sulfate protection of disc matrix not detailed"]},{"year":2022,"claim":"Established CHSY1 as a negative regulator of BMP signaling in cartilage, where its loss promotes endochondral osteogenesis.","evidence":"Lentiviral Chsy1 knockdown in ATDC5 chondrocytes with BMP inhibitor rescue and primary OA chondrocyte assays","pmids":["35390446"],"confidence":"Medium","gaps":["How chondroitin sulfate restrains BMP signaling mechanistically not defined","Single-lab, knockdown-based evidence"]},{"year":2023,"claim":"Demonstrated that CHSY1-synthesized chondroitin sulfate stabilizes versican in peripheral nerve matrix and influences functional nerve recovery.","evidence":"In vivo siRNA knockdown in a rat neurorrhaphy model with imaging, Western blot, and electrophysiology","pmids":["37175152"],"confidence":"Medium","gaps":["Direct CHSY1–versican biochemical relationship not isolated","Single model system"]},{"year":2023,"claim":"Linked CHSY1 to tumor immune evasion, showing it drives CD8+ T cell exhaustion and PD-L1 upregulation via succinate metabolism and PI3K/AKT/HIF1A in colorectal liver metastasis.","evidence":"In vivo CRISPR screen, knockdown validation, and metabolomics","pmids":["37749638"],"confidence":"Medium","gaps":["Connection between glycosyltransferase activity and metabolic reprogramming not mechanistically resolved","Single-lab study"]},{"year":2025,"claim":"Resolved the enzymatic architecture of chondroitin sulfate polymerization, showing CHSY1 is the catalytic bifunctional subunit within heterodimeric complexes with CHPF/CHPF2 that elongate chains non-processively.","evidence":"Cryo-EM of CHSY3-CHPF complex, in vitro glycosylation with fluorescent substrates, and mutational/complementation analysis (preprint)","pmids":["bio_10.1101_2025.03.21.644485"],"confidence":"High","gaps":["Direct structure of CHSY1-containing complex (versus CHSY3-CHPF) not solved","Preprint, not yet peer-reviewed"]},{"year":2026,"claim":"Identified a CANT1/β-catenin/TCF4 transcriptional axis that activates CHSY1 to sustain GAG and proteoglycan production in skeletal cells.","evidence":"Protein-binding assays, nuclear translocation, CHSY1 activation assays, and ECM component quantification","pmids":["41928906"],"confidence":"Medium","gaps":["Direct TCF4 binding at the CHSY1 promoter not mapped","Abstract-level detail only"]},{"year":null,"claim":"How CHSY1-generated chondroitin sulfate chains are mechanistically read out by distinct downstream pathways (NOTCH, BMP, Hedgehog, immune-metabolic) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking chain structure to selective pathway modulation","Structure of a CHSY1-specific polymerizing complex unsolved","In vivo separation of matrix versus signaling functions incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,13]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,13]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[11,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2]}],"complexes":["CHSY1-CHPF heterodimer","CHSY1-CHPF2 heterodimer"],"partners":["CHPF","CHPF2","CSGALNACT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86X52","full_name":"Chondroitin sulfate synthase 1","aliases":["Chondroitin glucuronyltransferase 1","Chondroitin synthase 1","ChSy-1","Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase 1","N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 1","N-acetylgalactosaminyltransferase 1"],"length_aa":802,"mass_kda":91.8,"function":"Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Involved in the negative control of osteogenesis likely through the modulation of NOTCH signaling","subcellular_location":"Golgi apparatus, Golgi stack membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/Q86X52/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHSY1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHSY1","total_profiled":1310},"omim":[{"mim_id":"616615","title":"CHONDROITIN SULFATE N-ACETYLGALACTOSAMINYLTRANSFERASE 1; CSGALNACT1","url":"https://www.omim.org/entry/616615"},{"mim_id":"610405","title":"CHONDROITIN POLYMERIZING FACTOR; CHPF","url":"https://www.omim.org/entry/610405"},{"mim_id":"609963","title":"CHONDROITIN SULFATE SYNTHASE 3; CHSY3","url":"https://www.omim.org/entry/609963"},{"mim_id":"608183","title":"CHONDROITIN SULFATE SYNTHASE 1; CHSY1","url":"https://www.omim.org/entry/608183"},{"mim_id":"608037","title":"CHONDROITIN POLYMERIZING FACTOR 2; CHPF2","url":"https://www.omim.org/entry/608037"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CHSY1"},"hgnc":{"alias_symbol":["KIAA0990","CSS1"],"prev_symbol":[]},"alphafold":{"accession":"Q86X52","domains":[{"cath_id":"3.90.550.50","chopping":"88-308","consensus_level":"high","plddt":90.1244,"start":88,"end":308},{"cath_id":"3.10.450","chopping":"377-477","consensus_level":"high","plddt":89.2464,"start":377,"end":477},{"cath_id":"3.90.550.10","chopping":"535-782","consensus_level":"high","plddt":93.4981,"start":535,"end":782},{"cath_id":"4.10.810","chopping":"315-360","consensus_level":"medium","plddt":90.7883,"start":315,"end":360}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86X52","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86X52-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86X52-F1-predicted_aligned_error_v6.png","plddt_mean":83.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHSY1","jax_strain_url":"https://www.jax.org/strain/search?query=CHSY1"},"sequence":{"accession":"Q86X52","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86X52.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86X52/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86X52"}},"corpus_meta":[{"pmid":"21129727","id":"PMC_21129727","title":"Loss of CHSY1, a secreted FRINGE enzyme, causes syndromic brachydactyly in humans via increased NOTCH signaling.","date":"2010","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21129727","citation_count":73,"is_preprint":false},{"pmid":"22280990","id":"PMC_22280990","title":"Chondroitin sulfate synthase 1 (Chsy1) is required for bone development and digit patterning.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22280990","citation_count":68,"is_preprint":false},{"pmid":"31767633","id":"PMC_31767633","title":"FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1.","date":"2020","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31767633","citation_count":57,"is_preprint":false},{"pmid":"28652022","id":"PMC_28652022","title":"CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28652022","citation_count":45,"is_preprint":false},{"pmid":"37749638","id":"PMC_37749638","title":"CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37749638","citation_count":37,"is_preprint":false},{"pmid":"30417274","id":"PMC_30417274","title":"Transforming growth factor-β1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells.","date":"2018","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/30417274","citation_count":36,"is_preprint":false},{"pmid":"36047655","id":"PMC_36047655","title":"Sensory Nerve Maintains Intervertebral Disc Extracellular Matrix Homeostasis Via CGRP/CHSY1 Axis.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36047655","citation_count":30,"is_preprint":false},{"pmid":"30344756","id":"PMC_30344756","title":"CHSY1 promoted proliferation and suppressed apoptosis in colorectal cancer through regulation of the NFκB and/or caspase-3/7 signaling pathway.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30344756","citation_count":25,"is_preprint":false},{"pmid":"26356269","id":"PMC_26356269","title":"TGF-β Induces Up-Regulation of Chondroitin Sulfate Synthase 1 (CHSY1) in Nucleus Pulposus Cells Through MAPK Signaling.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26356269","citation_count":20,"is_preprint":false},{"pmid":"34716872","id":"PMC_34716872","title":"LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34716872","citation_count":18,"is_preprint":false},{"pmid":"33833527","id":"PMC_33833527","title":"LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33833527","citation_count":17,"is_preprint":false},{"pmid":"30809816","id":"PMC_30809816","title":"Endothelin-1 increases CHSY-1 expression in aortic endothelial cells via transactivation of transforming growth factor β type I receptor induced by type B receptor endothelin-1.","date":"2019","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30809816","citation_count":15,"is_preprint":false},{"pmid":"23811343","id":"PMC_23811343","title":"A chondroitin synthase-1 (ChSy-1) missense mutation in a patient with neuropathy impairs the elongation of chondroitin sulfate chains initiated by chondroitin N-acetylgalactosaminyltransferase-1.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23811343","citation_count":11,"is_preprint":false},{"pmid":"34412565","id":"PMC_34412565","title":"CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration.","date":"2021","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/34412565","citation_count":10,"is_preprint":false},{"pmid":"24269551","id":"PMC_24269551","title":"A novel CHSY1 gene mutation underlies Temtamy preaxial brachydactyly syndrome in a Pakistani family.","date":"2013","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24269551","citation_count":10,"is_preprint":false},{"pmid":"30401686","id":"PMC_30401686","title":"Polyamines stimulate the CHSY1 synthesis through the unfolding of the RNA G-quadruplex at the 5'-untraslated region.","date":"2018","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30401686","citation_count":10,"is_preprint":false},{"pmid":"35390446","id":"PMC_35390446","title":"Chsy1 deficiency reduces extracellular matrix productions and aggravates cartilage injury in osteoarthritis.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35390446","citation_count":9,"is_preprint":false},{"pmid":"37175152","id":"PMC_37175152","title":"Targeting Chondroitin Sulphate Synthase 1 (Chsy1) Promotes Axon Growth Following Neurorrhaphy by Suppressing Versican Accumulation.","date":"2023","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37175152","citation_count":4,"is_preprint":false},{"pmid":"34837677","id":"PMC_34837677","title":"EGF Receptor Transactivation by Endothelin-1 Increased CHSY-1 Mediated by NADPH Oxidase and Phosphorylation of ERK1/2.","date":"2021","source":"Cell journal","url":"https://pubmed.ncbi.nlm.nih.gov/34837677","citation_count":4,"is_preprint":false},{"pmid":"36643258","id":"PMC_36643258","title":"Hsa_circ_0005050 regulated the progression of oral squamous cell carcinoma via miR-487a-3p/CHSY1 axis.","date":"2022","source":"Journal of dental sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36643258","citation_count":2,"is_preprint":false},{"pmid":"41928906","id":"PMC_41928906","title":"Dysregulation of the Cant1/β-Catenin/TCF4-CHSY1 Axis Underpins Impaired ECM Biosynthesis in Skeletal Disorders.","date":"2026","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/41928906","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.08.06.606424","title":"Astrocyte extracellular matrix modulates neuronal dendritic development","date":"2024-08-06","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.06.606424","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.21.644485","title":"Structural basis for human chondroitin sulfate chain polymerization","date":"2025-03-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.21.644485","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14164,"output_tokens":3862,"usd":0.050211,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11630,"output_tokens":4424,"usd":0.084375,"stage2_stop_reason":"end_turn"},"total_usd":0.134586,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"CHSY1 is a secreted FRINGE enzyme required for chondroitin sulfate biosynthesis and for modulation of NOTCH signaling; loss of CHSY1 triggers massive production of JAG1 and subsequent NOTCH activation, which is reversed by wild-type but not catalytically dead CHSY1, demonstrating that its Fringe enzymatic activity is required for NOTCH regulation.\",\n      \"method\": \"Patient fibroblast secretion assay, RNAi knockdown in osteoblasts and glioblastoma cells, rescue with wild-type vs. catalytic-dead CHSY1 construct, zebrafish chsy1 morpholino knockdown\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (patient cells, RNAi, catalytic-dead rescue, in vivo zebrafish model) across human and fish systems\",\n      \"pmids\": [\"21129727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Chsy1 is required for joint patterning and bone density in mice; Chsy1 knockout causes chondrodysplasia, decreased bone density, and ectopic joint formation in distal digits associated with a shift in cell orientation and imbalance in chondroitin sulfation.\",\n      \"method\": \"Chsy1 knockout mouse model; skeletal phenotype analysis, chondroitin sulfation assessment\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined skeletal and molecular phenotype, replicated human disease context\",\n      \"pmids\": [\"22280990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CHSY1 has two glycosyltransferase activities (GlcUA transferase and GalNAc transferase) responsible for adding disaccharide units to chondroitin sulfate chains; the F362S missense mutation reduces both activities by ~50% and abrogates the cooperative elongation of chains initiated by chondroitin N-acetylgalactosaminyltransferase-1 (CSGALNACT1), demonstrating that CHSY1 regulates chain number/length cooperatively with CSGALNACT1.\",\n      \"method\": \"Recombinant wild-type and F362S mutant enzyme expression, in vitro glycosyltransferase activity assay, cell-based complementation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis, single lab but multiple assays (both transferase activities + cooperative elongation tested)\",\n      \"pmids\": [\"23811343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGF-β induces CHSY1 expression in nucleus pulposus cells via MAPK signaling and activation of transcription factors c-Jun and Sp1; knockdown of c-Jun or Sp1 reduces TGF-β-mediated CHSY1 promoter activity and sulfated GAG accumulation; silencing CHSY1 reduces TGF-β-induced sulfated GAG accumulation.\",\n      \"method\": \"Real-time PCR, Western blot, lentiviral knockdown, CHSY1 promoter reporter assay in nucleus pulposus cells\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter + lentiviral KD with multiple pathway intermediates, single lab\",\n      \"pmids\": [\"26356269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CHSY1 promotes hepatocellular carcinoma cell migration, invasion, and EMT by increasing cell-surface chondroitin sulfate that facilitates sonic hedgehog binding and Hedgehog pathway signaling; pharmacological Hedgehog inhibition reverses CHSY1-induced migration, invasion, and lung metastasis.\",\n      \"method\": \"CHSY1 overexpression and silencing in HCC cell lines, Hedgehog pathway inhibitor (vismodegib), in vivo lung metastasis assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with pharmacological rescue and in vivo model, single lab\",\n      \"pmids\": [\"28652022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TGF-β1-mediated upregulation of CHSY1 mRNA in vascular smooth muscle cells occurs via a ROS/NADPH oxidase (Nox)-dependent pathway involving Smad2 linker region phosphorylation and MAPK activation; Nox inhibitors (DPI, apocynin) block both Smad2 linker phosphorylation and CHSY1 mRNA induction.\",\n      \"method\": \"Western blotting for signaling intermediates, qRT-PCR for gene expression, pharmacological inhibition of Nox, fluorescence-based ROS measurement in VSMCs\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors with orthogonal readouts, single lab\",\n      \"pmids\": [\"30417274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Polyamines stimulate CHSY1 protein synthesis by destabilizing an RNA G-quadruplex (G4) structure in the 5'-UTR of CHSY1 mRNA (positions -202 to -117 relative to initiation codon); site-directed mutagenesis that prevents G4 formation abolishes the polyamine-stimulated increase in CHSY1 synthesis.\",\n      \"method\": \"Polyamine depletion/supplementation, CHSY1 protein quantification, NMR/structural analysis of 5'-UTR G4, site-directed mutagenesis of G4 sequences\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural (NMR) + mutagenesis + biochemical assay in single rigorous study demonstrating mechanism\",\n      \"pmids\": [\"30401686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Endothelin-1 increases CHSY-1 protein levels in bovine aortic endothelial cells via ETB receptor signaling through Rho kinase and actin cytoskeletal rearrangement, leading to TGF-β type I receptor transactivation and Smad2C phosphorylation; this pathway does not involve MMPs.\",\n      \"method\": \"Western blotting with pharmacological inhibitors (BQ788, Y27632, cytochalasin D, GM6001) in BAECs\",\n      \"journal\": \"The Journal of pharmacy and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors identifying pathway order, single lab\",\n      \"pmids\": [\"30809816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ET-1 increases CHSY1 expression in human VSMCs through transactivation of both EGF receptor and TGF-β receptor; EGF receptor transactivation by ET-1 is dependent on NADPH oxidase (NOX) and ERK1/2 phosphorylation.\",\n      \"method\": \"Western blot with pharmacological inhibitors (bosentan, AG1478, DPI, SB431542) in human VSMCs\",\n      \"journal\": \"Cell journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors with orthogonal readouts, single lab\",\n      \"pmids\": [\"34837677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CGRP from sensory nerves maintains intervertebral disc chondroitin sulfate homeostasis by regulating nucleus pulposus cell CHSY1 expression via the CGRP receptor component RAMP1 and CREB signaling; CHSY1 knockout mice phenocopy sensory denervation-induced ECM disorder, placing CHSY1 downstream of the CGRP/RAMP1/CREB axis.\",\n      \"method\": \"Genetic sensory denervation, CGRP knockdown mouse model, CHSY1 knockout mice, in vitro CGRP treatment with RAMP1/CREB pathway analysis\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (CHSY1 KO rescues denervation phenotype), multiple in vivo models, in vitro pathway validation\",\n      \"pmids\": [\"36047655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Chsy1 deficiency in chondrocytes reduces extracellular matrix production and promotes endochondral osteogenesis by upregulating BMP signaling; BMP inhibitor LDN193189 rescues the ECM and osteogenesis defects caused by Chsy1 knockdown, placing Chsy1 as a negative regulator of BMP signaling in cartilage.\",\n      \"method\": \"Lentiviral Chsy1 knockdown in ATDC5 chondrocytes, BMP inhibitor rescue, gene expression analysis (Col2a1, Sox9, Col10a1, Runx2, Mmp13, Mmp3), primary OA rat chondrocyte experiments\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KD with pharmacological rescue and overexpression confirmation, single lab\",\n      \"pmids\": [\"35390446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Chsy1 knockdown at peripheral nerve lesion sites decreases versican core protein accumulation in perineurium, associated with functional recovery of compound muscle action potential after end-to-side neurorrhaphy, indicating that CHSY1-synthesized chondroitin sulfate chains stabilize versican in the extracellular matrix.\",\n      \"method\": \"In vivo siRNA transfection in rat neurorrhaphy model, confocal microscopy, Western blotting, electrophysiology (compound muscle action potential)\",\n      \"journal\": \"Molecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD with molecular and functional readouts, single lab\",\n      \"pmids\": [\"37175152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHSY1 promotes CD8+ T cell exhaustion and PD-L1 upregulation through activation of the succinate metabolism pathway and the PI3K/AKT/HIF1A pathway, facilitating colorectal cancer liver metastasis; artemisinin inhibits CHSY1 activity and synergizes with anti-PD1.\",\n      \"method\": \"CRISPR/Cas9 in vivo mouse screen, in vitro and in vivo CHSY1 KD experiments, metabolomic analysis\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen + in vivo/in vitro validation + metabolomics, single lab\",\n      \"pmids\": [\"37749638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CHSY1 forms four heterodimeric complexes (CHSY1-CHPF, CHSY1-CHPF2, CHSY3-CHPF, CHSY3-CHPF2) that polymerize chondroitin sulfate chains; cryo-EM structure and mutational analysis confirm that CHSY1 (and CHSY3) are the catalytically active bifunctional glycosyltransferases, while CHPF and CHPF2 play a stabilizing role; chain polymerization follows a non-processive, disruptive mechanism.\",\n      \"method\": \"Cryo-EM structure of CHSY3-CHPF complex, in vitro glycosylation assay with fluorescent substrates, mutational analysis of catalytic sites, in cellulo complementation assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure + in vitro reconstitution + mutagenesis + cell-based complementation in single preprint study\",\n      \"pmids\": [\"bio_10.1101_2025.03.21.644485\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CANT1 binds and stabilizes β-catenin, which translocates to the nucleus to activate CHSY1 transcription via TCF4; loss of CANT1/β-catenin signaling reduces CHSY1 expression and consequently reduces GAG and proteoglycan (ACAN) and COL2α1 production, causing skeletal ECM defects.\",\n      \"method\": \"Protein binding assays (CANT1-β-catenin interaction), nuclear translocation assay, CHSY1 gene activation assays, ECM component quantification in skeletal cells\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assay plus downstream gene activation and ECM readouts, single lab, abstract-level detail\",\n      \"pmids\": [\"41928906\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHSY1 is a bifunctional glycosyltransferase (GlcUA and GalNAc transferase) that, as part of heterodimeric complexes with CHPF or CHPF2, polymerizes chondroitin sulfate chains on proteoglycans via a non-processive mechanism; it is secreted and acts as a FRINGE enzyme to attenuate NOTCH signaling, modulates BMP signaling in cartilage, facilitates sonic hedgehog binding at the cell surface, regulates versican stability in the ECM, and is transcriptionally controlled by TGF-β/MAPK, CGRP/RAMP1/CREB, and CANT1/β-catenin/TCF4 pathways, with its own translation regulated post-transcriptionally by polyamine-mediated unfolding of a 5'-UTR RNA G-quadruplex.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CHSY1 is a secreted bifunctional glycosyltransferase that polymerizes chondroitin sulfate chains on proteoglycans, thereby governing extracellular matrix composition and several developmental signaling pathways [#0, #2]. It carries two distinct catalytic activities—glucuronic acid (GlcUA) transferase and N-acetylgalactosamine (GalNAc) transferase—that add disaccharide units during chain elongation, acting cooperatively with CSGALNACT1 to control chain number and length [#2]. CHSY1 functions within heterodimeric complexes with the stabilizing subunits CHPF or CHPF2 and elongates chains by a non-processive, disruptive mechanism [#13]. Through its enzymatic output, CHSY1 acts as a FRINGE enzyme that restrains NOTCH signaling: its loss drives excess JAG1 production and NOTCH activation, a phenotype rescued by catalytically active but not catalytic-dead enzyme [#0]. The chondroitin sulfate it produces additionally negatively regulates BMP signaling in chondrocytes [#10], facilitates cell-surface sonic hedgehog binding [#4], and stabilizes the matrix proteoglycan versican [#11]. In vivo, CHSY1 is required for skeletal development, controlling joint patterning, bone density, and chondroitin sulfation balance [#1], and its activity sustains intervertebral disc matrix homeostasis downstream of sensory CGRP/RAMP1/CREB signaling [#9]. CHSY1 expression is induced transcriptionally by TGF-\\u03b2 via MAPK/c-Jun/Sp1 [#3] and by CANT1/\\u03b2-catenin/TCF4 signaling [#14], while its translation is controlled post-transcriptionally by polyamine-mediated unfolding of a 5'-UTR RNA G-quadruplex [#6]. CHSY1 also promotes tumor progression in hepatocellular and colorectal carcinoma through Hedgehog and PI3K/AKT/HIF1A-coupled metabolic mechanisms [#4, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Established that CHSY1's chondroitin sulfate-synthesizing enzymatic activity is functionally required to restrain NOTCH signaling, defining it as a FRINGE enzyme rather than a passive matrix builder.\",\n      \"evidence\": \"Patient fibroblast secretion assay, RNAi in osteoblasts/glioblastoma, catalytic-dead rescue, and zebrafish morpholino knockdown\",\n      \"pmids\": [\"21129727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between chondroitin sulfate output and JAG1/NOTCH suppression not mechanistically resolved\", \"Does not define the enzymatic reaction chemistry\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that Chsy1 is essential in vivo for skeletal patterning, connecting its biochemical role to joint formation, bone density, and chondroitin sulfation balance.\",\n      \"evidence\": \"Chsy1 knockout mouse with skeletal and chondroitin sulfation phenotyping\",\n      \"pmids\": [\"22280990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway driving the ectopic joint phenotype not identified at this stage\", \"Cell-autonomous versus matrix-mediated effects not separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined CHSY1's dual catalytic activities and showed it cooperates with CSGALNACT1, explaining how it regulates chondroitin chain number and length.\",\n      \"evidence\": \"Recombinant wild-type/F362S enzyme in vitro glycosyltransferase assays and cell-based complementation\",\n      \"pmids\": [\"23811343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of bifunctional catalysis not resolved\", \"Composition of the active enzyme complex not yet defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the first transcriptional input to CHSY1, showing TGF-\\u03b2 induces it through MAPK/c-Jun/Sp1 to drive sulfated GAG accumulation.\",\n      \"evidence\": \"Promoter reporter, lentiviral knockdown, and expression analysis in nucleus pulposus cells\",\n      \"pmids\": [\"26356269\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct c-Jun/Sp1 binding to the CHSY1 promoter not mapped\", \"Single cell type tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed post-transcriptional control of CHSY1, showing polyamines stimulate its translation by destabilizing a 5'-UTR RNA G-quadruplex.\",\n      \"evidence\": \"Polyamine depletion/supplementation, NMR structural analysis, and G4-disrupting mutagenesis\",\n      \"pmids\": [\"30401686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger linking polyamine levels to chondroitin sulfate demand not established\", \"Trans-acting factors recognizing the G4 not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended TGF-\\u03b2 control of CHSY1 to vascular smooth muscle via a ROS/Nox-dependent Smad2 linker phosphorylation route.\",\n      \"evidence\": \"Pharmacological Nox inhibition with signaling and qRT-PCR readouts in VSMCs\",\n      \"pmids\": [\"30417274\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based pathway inference without genetic confirmation\", \"Direct effect on chondroitin sulfate output not measured\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped an endothelin-1/ETB receptor pathway that raises CHSY1 protein through Rho kinase and TGF-\\u03b2 receptor transactivation in endothelial cells.\",\n      \"evidence\": \"Western blot with sequential pharmacological inhibitors in bovine aortic endothelial cells\",\n      \"pmids\": [\"30809816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relies entirely on pharmacological inhibitors\", \"Transcriptional versus translational control not distinguished\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ET-1 regulation of CHSY1 in human VSMCs converges on dual EGFR and TGF-\\u03b2 receptor transactivation, with EGFR arm NOX/ERK-dependent.\",\n      \"evidence\": \"Western blot with multiple inhibitors in human VSMCs\",\n      \"pmids\": [\"34837677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic loss-of-function validation\", \"Downstream chondroitin sulfate consequences not assessed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed CHSY1 downstream of sensory CGRP/RAMP1/CREB signaling as the effector maintaining intervertebral disc chondroitin sulfate homeostasis.\",\n      \"evidence\": \"Genetic sensory denervation, CGRP knockdown, and CHSY1 knockout mice with in vitro pathway validation\",\n      \"pmids\": [\"36047655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CREB occupancy of the CHSY1 locus not shown\", \"Mechanism of chondroitin sulfate protection of disc matrix not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established CHSY1 as a negative regulator of BMP signaling in cartilage, where its loss promotes endochondral osteogenesis.\",\n      \"evidence\": \"Lentiviral Chsy1 knockdown in ATDC5 chondrocytes with BMP inhibitor rescue and primary OA chondrocyte assays\",\n      \"pmids\": [\"35390446\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How chondroitin sulfate restrains BMP signaling mechanistically not defined\", \"Single-lab, knockdown-based evidence\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated that CHSY1-synthesized chondroitin sulfate stabilizes versican in peripheral nerve matrix and influences functional nerve recovery.\",\n      \"evidence\": \"In vivo siRNA knockdown in a rat neurorrhaphy model with imaging, Western blot, and electrophysiology\",\n      \"pmids\": [\"37175152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CHSY1\\u2013versican biochemical relationship not isolated\", \"Single model system\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked CHSY1 to tumor immune evasion, showing it drives CD8+ T cell exhaustion and PD-L1 upregulation via succinate metabolism and PI3K/AKT/HIF1A in colorectal liver metastasis.\",\n      \"evidence\": \"In vivo CRISPR screen, knockdown validation, and metabolomics\",\n      \"pmids\": [\"37749638\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between glycosyltransferase activity and metabolic reprogramming not mechanistically resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved the enzymatic architecture of chondroitin sulfate polymerization, showing CHSY1 is the catalytic bifunctional subunit within heterodimeric complexes with CHPF/CHPF2 that elongate chains non-processively.\",\n      \"evidence\": \"Cryo-EM of CHSY3-CHPF complex, in vitro glycosylation with fluorescent substrates, and mutational/complementation analysis (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.21.644485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structure of CHSY1-containing complex (versus CHSY3-CHPF) not solved\", \"Preprint, not yet peer-reviewed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified a CANT1/\\u03b2-catenin/TCF4 transcriptional axis that activates CHSY1 to sustain GAG and proteoglycan production in skeletal cells.\",\n      \"evidence\": \"Protein-binding assays, nuclear translocation, CHSY1 activation assays, and ECM component quantification\",\n      \"pmids\": [\"41928906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TCF4 binding at the CHSY1 promoter not mapped\", \"Abstract-level detail only\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CHSY1-generated chondroitin sulfate chains are mechanistically read out by distinct downstream pathways (NOTCH, BMP, Hedgehog, immune-metabolic) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking chain structure to selective pathway modulation\", \"Structure of a CHSY1-specific polymerizing complex unsolved\", \"In vivo separation of matrix versus signaling functions incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 13]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [11, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [\n      \"CHSY1-CHPF heterodimer\",\n      \"CHSY1-CHPF2 heterodimer\"\n    ],\n    \"partners\": [\n      \"CHPF\",\n      \"CHPF2\",\n      \"CSGALNACT1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}